Guardian Therapeutics

Guardian Therapeutics is a private, pre-revenue biotech pioneering the development of aptamer drug conjugates (ApDCs) and other aptamer therapeutics. The company's platform enables rapid discovery of therapeutic aptamers with high affinity and stability, targeting a broad pipeline across hematology, gastroenterology, dermatology, and oncology. Led by co-founders CEO Jim Gilbert, MD, and CSO Shuhao Zhu, PhD, the company is advancing its platform and pipeline from its headquarters in Lowell, Massachusetts. Guardian's strategy positions it to capitalize on the potential advantages of aptamers over traditional antibody-based therapies.

Proprietary platform for the discovery and development of stable, high-affinity nucleic acid aptamers and Aptamer-Drug Conjugates (ApDCs), utilizing deep sequencing, modified nucleotide chemistries, and high-throughput synthesis.

Guardian competes with large pharma and biotech companies developing Antibody-Drug Conjugates (ADCs) and other targeted biologics. It also competes within the oligonucleotide space against companies like Ionis, Alnylam, and newer entrants developing aptamers (e.g., Archemix, Aptamer Group). Differentiation hinges on demonstrating clinical efficacy and the proposed CMC advantages of ApDCs over ADCs.